CRL - Charles River Laboratories International, Inc.

Charles River Laboratories to Present at William Blair and Jefferies Conferences

WILMINGTON, Mass., June 05, 2023--Charles River Laboratories to present at William Blair and Jefferies conferences.

• 
  Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

  Business Wire
• 
  Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference

  Business Wire

Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory

WILMINGTON, Mass., May 31, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSourceSM at Wheeler Bio’s current good manufacturing practice (CGMP) biologics manufacturing facility in Oklahoma City, OK. Deployed on-site at a client’s facility, RightSource is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable qu

Charles River Laboratories Announces First-Quarter 2023 Results

WILMINGTON, Mass., May 11, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.

Charles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID

WILMINGTON, Mass., May 01, 2023--Charles River launches Accugenix NGS for bacterial identification and fungal ID; announces partner lab initiative to expand global coverage.

Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call

WILMINGTON, Mass., April 11, 2023--Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call

Charles River Laboratories Showcases End-to-End Oncology Capabilities at AACR 2023

WILMINGTON, Mass., April 10, 2023--Charles River highlights the importance of next-generation technologies for oncology drug discovery at AACR 2023.

Charles River Laboratories to Present at Barclays Global Healthcare Conference

WILMINGTON, Mass., March 13, 2023--Charles River Laboratories To Present At Barclays Global Healthcare Conference

Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data

WILMINGTON, Mass., March 13, 2023--Charles River launches Apollo, an intuitive customer platform that provides secure cloud-based access to real-time toxicology study data.

Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing

WILMINGTON, Mass., March 09, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance

WILMINGTON, Mass., February 22, 2023--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance

Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--Charles River and Pioneering Medicines enter agreement to deploy Logica to create optimized small molecules that will lead to novel therapies.

Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration

WILMINGTON, Mass., February 15, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.

Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein

WILMINGTON, Mass., February 13, 2023--Charles River launches their novel IgY-based HCP ELISA kit, which achieves industry leading rates for sensitivity and specificity.

Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call

WILMINGTON, Mass., February 09, 2023--Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call

Charles River Laboratories Acquires SAMDI Tech

WILMINGTON, Mass., January 30, 2023--Charles River Laboratories Acquires SAMDI Tech

iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of

Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance

WILMINGTON, Mass., January 18, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.

Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products

WILMINGTON, Mass., January 16, 2023--Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrimeTM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials. CliniPrime products provide rapid access to starting materials for cell, and gene-modified cell therapies with a standardized production process for high-quality GMP-compliant products. All CliniPrime products meet the essential regulatory guidelines for clinical trial

Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs

WILMINGTON, Mass., January 12, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience. The platform significantly reduces plasmid development and production timelines while streamlining the development journey for cell and gene therapy and vaccine developers with a focus on product quality and consistency.

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

WILMINGTON, Mass., January 09, 2023--Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors

WILMINGTON, Mass., December 06, 2022--Charles River Laboratories Adds Craig B. Thompson To Board of Directors

Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection

WILMINGTON, Mass., December 01, 2022--Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles River’s data integrity compliant, fully robotic instrument, capable of processing both undiluted or complex, serial dilutions for water, in-process, and final product testing via Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology in a fully enclosed system. Pow

Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program

WILMINGTON, Mass., November 28, 2022--Charles River recently opened its first location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois.

Charles River Laboratories to Present at November Investor Conferences

WILMINGTON, Mass., November 14, 2022--Charles River Laboratories To Present At November Investor Conferences

Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022

WILMINGTON, Mass., November 10, 2022--Charles River announced that its team of neuroscience drug discovery experts will present 23 scientific posters at Neuroscience 2022.